The Burden of Acute Coronary Syndromes in the United Kingdom

The Burden of Acute Coronary Syndromes in the United Kingdom

Tim Wilsdon
Life Sciences | Pharmaceuticals

AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.

Download PDF